Latest Breaking News On - Ocular surgery - Page 3 : comparemela.com

Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases

Peter K. Kaiser, M.D., a world-renowned ophthalmologist and retinal disease expert, to serve as Chief Medical Advisor – RetinaRabia Gurses Ozden, M.D. promoted to Chief Medical OfficerMichael Goldstein, M.D. to transition from Chief Medical Officer and President Ophthalmology to Chief Strategy AdvisorBEDFORD, Mass.-.

United statesScott corningAntony mattessichGurses ozdenMichael goldsteinRabia gurses ozdenChris brinzeyPeterk kaiserLewr wassermanDonald notmanAmerican society of retina specialists honorBascom palmer eye instituteOphthalmology researchOcular therapeutix incCompany onCleveland clinic foundation

Palatin Hosting Key Opinion Leader Webinar on Dry Eye Disease

/PRNewswire/ Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that.

United statesLong islandNew york universityNew yorkNew providenceTufts medical centerMichaelb raizmanEricd donnenfeldPalatin technologieMichael raizmanRefractive committeeCorneal fellowship programDartmouth collegeDartmouth medical schoolUniversity of michiganImmunology group

Dr Eric D Donnenfeld of OCLI Vision Named America s Best Eye Doctor by Newsweek

Dr Eric D Donnenfeld of OCLI Vision Named America s Best Eye Doctor by Newsweek
prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesNew jerseyLong islandGarden cityNew providenceEricd donnenfeldMarguerite mcdonaldTom burkeGreg wappettHenryd perryHenry perryAmerican academy of ophthalmologyNassau surgical societyBest eye doctorLifetime achievement award

Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis

Highlights of Recent Positive Data from Nyxol's Phase 3 Registration Trial Roundtable Discussion by 3 KOLs with Unique Perspectives and Distinct Patient .

United statesSusan bentonMina soochPeterk kaiserPeter kaiserPaulm karpeckiCorey davisOcuphire pharmaJay peposeSciences at washington university school of medicineSchool of medicinePennsylvania college of optometryNational institute of healthBrandeis universityGeorgetown university medical centerGaddie eye centers in louisville

Palatin Hosting Key Opinion Leader Webinar in Role of Melanocortin Agonists in Inflammation and the Treatment of Ocular Indications

/PRNewswire/ Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that.

United statesCleveland clinicBoston universityLong islandReading centerNew yorkNew providenceSouth koreaCarl spanaGeorge ouslerAndrew taylorEric donnenfeldJohn doddKols andreww taylorPeterk kaiserTear film ocular surface society